Affordable Access

deepdyve-link
Publisher Website

Proactive Drug Monitoring Is Associated With Higher Persistence to Infliximab and Adalimumab Treatment and Lower Healthcare Utilization Compared With Reactive and Clinical Monitoring

Authors
  • Syed, Nauroz1
  • Tolaymat, Mazen2
  • Brown, Sara A3
  • Sivasailam, Barathi4
  • Cross, Raymond K2
  • 1 Department of Medicine, Division of Gastroenterology and Hepatology, Penn State Hershey College of Medicine, USA , (United States)
  • 2 Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, USA , (United States)
  • 3 Department of Medicine, Division of Gastroenterology and Hepatology, Vanderbilt University Medical Center, USA , (United States)
  • 4 Department of Medicine, Division of Internal Medicine, University of Maryland School of Medicine, USA , (United States)
Type
Published Article
Journal
Crohn's & Colitis 360
Publisher
Oxford University Press
Publication Date
Jun 05, 2020
Volume
2
Issue
3
Identifiers
DOI: 10.1093/crocol/otaa050
PMID: 32743546
PMCID: PMC7380488
Source
PubMed Central
Keywords
License
Unknown

Abstract

Proactive drug monitoring of infliximab and adalimumab in Crohn disease and ulcerative colitis was associated with a higher likelihood of staying on the original therapeutic at 1 and 2 years, as well as lower healthcare utilization.

Report this publication

Statistics

Seen <100 times